You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Henry Schein Inc. raised 2026 non-GAAP diluted EPS guidance to $5.50 to $5.56 from $5.29 to $5.39; global sales grew 4.0% to $3.5 billion, and U.S. dental merchandise sales grew 8.6%.
Henry Schein Inc reported quarterly net sales of $3,471 million, up 4.0%, and net income of $126 million versus $109 million a year earlier. Nine-month net sales were $10,297 million and net income was $340 million.
Henry Schein reported third-quarter sales of $3.5 billion, up 4.0%, GAAP diluted EPS of $1.06 and non-GAAP diluted EPS of $1.56, and raised FY2026 non-GAAP diluted EPS guidance to $5.50 to $5.56.
Henry Schein, Inc. appointed Emmanuel Caprais as CFO effective November 4, 2026, after starting as Senior Financial Advisor on October 12, 2026; Ronald N. South will transition to Senior Advisor after serving as CFO through November 3, 2026.
Henry Schein Inc amended and restated its revolving credit facility, increasing commitments from $1 billion to $1.25 billion and extending the termination date to September 19, 2031; the facility will support working capital, corporate purposes and potential acquisitions.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Henry Schein delivered 19.1% adjusted non-GAAP EPS growth, 8.6% U.S. dental merchandise growth and 20-basis-point non-GAAP operating-margin expansion, raised EPS and Adjusted EBITDA guidance, and repurchased $450 million of stock year to date. Weak value-added services, point-of-care diagnostic and vaccine sales, Brazil, digital-equipment sales, restructuring costs and the non-repeatable tariff benefit were notable concerns.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Acquisition growth | 0.7% | the three months ended June 27, 2026 filing | — |
| Adjusted EBITDA non-GAAP | 577M | first half of 2026 | — |
| Global Dental Distribution equipment internal sales growth | 2.2% | Q2 2026 | — |
| Global Dental Distribution merchandise internal sales growth | 5.9% | Q2 2026 | — |
| Global Medical Distribution internal sales growth | 3.9% | Q2 2026 | — |
| Global Specialty Products internal sales growth | 3.2% | Q2 2026 | — |
| Global Technology internal sales growth | 9.1% | Q2 2026 | — |
| Global Value-Added Services internal sales growth | 3.7% | Q2 2026 | — |
| Internal sales growth | 3.6% | first half of 2026 | — |
| Internally generated local currency dental sales growth | 4.9% | the three months ended June 27, 2026 filing | — |
| Internally generated local currency sales increase | 3.2% | the three months ended June 27, 2026 filing | — |
| Non-GAAP diluted EPS non-GAAP | $2.59 | first half of 2026 | — |
| Non-GAAP diluted EPS attributable to Henry Schein, Inc. non-GAAP | $1.27 | Second Quarter 2026 | — |
| Non-GAAP net income non-GAAP | 298M | first half of 2026 | — |
| Non-GAAP net income attributable to Henry Schein, Inc. non-GAAP | 145M | Second Quarter 2026 | — |
| Remaining stock repurchase authorization | $455M | end of Q2 2026 | — |
| Share repurchases total value | $200M | Q2 2026 | — |
| Share repurchases year-to-date total value | $325M | year-to-date 2026 | — |
| Shares repurchased | 2.6M | Q2 2026 | — |
| Shares repurchased year-to-date | 4.2M | year-to-date 2026 | — |
| Total Segment Operating Income non-GAAP | $292M | the three months ended June 27, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HSIC
this stock
Henry Schein Inc
|
$9.53B | +14.1% | +5.9% | 23.6 | 8.5% |
|
MCK
Mckesson Corp
|
$127.33B | +34.4% | +3.1% | 28.4 | 1.7% |
|
COR
Cencora, Inc.
|
$68.51B | +6.3% | +9.3% | 26.7 | 1.7% |
|
CAH
Cardinal Health Inc
|
$64.97B | +36.8% | +14.2% | — | 3.3% |
|
EBOSY
EBOS Group Limited
|
$2.37B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Henry Schein reported third-quarter sales of $3.5 billion, up 4.0%, GAAP diluted EPS of $1.06 and non-GAAP diluted EPS of $1.56, and raised FY2026 non-GAAP diluted EPS guidance to $5.50 to $5.56.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HSIC | +0.2% | -0.2% | +16.7% | +1.6% | +14.1% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.4% | +1.0% | +16.2% | +1.8% | +3.5% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
